Medical Advocates for Social Justice
Conference Abstract
from the
4th International Workshop on the Clinical Pharmacology
of HIV Therapy

Cannes, France  March 27-29, 2003
 

 
Effect of LPV trough level on the biological markers of cardiovascular risk in LPV/r treated HIV infected patients
[
Abstract 22]

Valerio L., Fontas E., Garraffo R., Pradier C., Durant J., Lavrut T., Dellamonica P.
 

Nice University Hospital, France.

 

Share this Abstract with a Colleague

Background:
In patients treated with Lopinavir / Ritonavir (LPV/r), no data are available about HDL-cholesterol (HDL-c) and Total Cholesterol / HDL-c Ratio (TC/HDL-c) which are established CVD predictive factors.

Methods: 
Lipids measurements (at LPV/r initiation time and every 3 months) and LPV and RTV plasma concentrations (at M3 and M6) were collected retrospectively in patients attending the clinic of the Infectiology’s Department. Dyslipidaemia was defined as TC > 6.2 mmol/l, HDL-c < 1 mmol/l, TC/HDL-c Ratio > 6.5 and TG > 2.3 mmol/l.


Results: 
142 patients treated with LPV/r were included (mean duration on LPV/r : 14.4 months). 126 (89%) patients had previously received a PI-containing regimen, 101 (71%) a NNRTI one and 6 (4%) were treatment naïve. At baseline, 17% of patients had high TC, 63% low HDL-c, 25% a high TC/HDL-c Ratio and 49% high TG. At M12, the mean HDL-c increase per patient was 21% and the proportion of dyslipidemic patients regarding HDL-c decreased to 53%. The proportion of patients with a Ratio > 6.5 rose to 41%. The increase in lipids means (mmol/l) is significant from the 3rd month (6th month for ratio) and still consistent over time until the 12th month : TC 6.09 vs 4.92 (p<0.001), HDL-c 1.06 vs 0.99 (p=0.001), TC/HDL-c ratio 6.11 vs 5.53 (p=0.03), TG 4.63 vs 2.88 (p=0.04). Among the patients with available LPV and RTV plasma determinations at M3 (n=30), a higher LPV trough concentration was observed in those with high TG (6.78 vs 3.02 mg/l, p=0.05). At M6 (n=15), the elevated ratio group had also a higher LPV trough value (9.19 vs 0.96, p=0.02).

Conclusion:

Our results suggest that LPV/r may induce a significant rise in the HDL-c level, even after a long term exposure. However, TC/HDL-c ratio appears to increase significantly over the study time traducing a potential elevation of the CVD risk. These preliminary results provide the rational for a more precise investigation of the possible role of therapeutic drug monitoring in the prevention of dyslipidaemia in LPV/r treated patients.


Main New/Newsworthy KLS Clinical Pharm Main Page Cannes Conference Index      

Effect of LPV trough level on the biological markers of cardiovascular risk in
LPV/r treated HIV infected patients
4th International Workshop on the Clinical Pharmacology of HIV Therapy

A Medical Advocates for Social Justice Update